Pointe Capital Management LLC Acquires New Position in Stryker Corporation $SYK

Pointe Capital Management LLC acquired a new position in shares of Stryker Corporation (NYSE:SYK) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 1,594 shares of the medical technology company’s stock, valued at approximately $502,000.

A number of other large investors have also recently bought and sold shares of the business. Gables Capital Management Inc. bought a new position in shares of Stryker during the second quarter valued at approximately $25,000. Kilter Group LLC bought a new stake in shares of Stryker in the 2nd quarter worth approximately $25,000. Godfrey Financial Associates Inc. acquired a new position in Stryker during the 4th quarter valued at approximately $26,000. Sankala Group LLC acquired a new position in Stryker during the 4th quarter valued at approximately $26,000. Finally, Compass Financial Management LLC bought a new position in Stryker during the 2nd quarter worth $27,000. Institutional investors own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on SYK shares. Canaccord Genuity Group dropped their target price on Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Argus set a $370.00 price target on shares of Stryker in a research report on Thursday, July 9th. Truist Financial increased their price objective on shares of Stryker from $330.00 to $340.00 and gave the stock a “hold” rating in a report on Friday, July 31st. Leerink Partners cut their price objective on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a research report on Friday, June 5th. Finally, Citigroup reissued a “buy” rating on shares of Stryker in a research note on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $386.28.

Stryker Stock Up 1.0%

Shares of Stryker stock opened at $331.06 on Wednesday. The business’s fifty day moving average price is $327.80 and its two-hundred day moving average price is $331.95. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The company has a market capitalization of $126.98 billion, a P/E ratio of 34.31, a PEG ratio of 2.09 and a beta of 0.76. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $396.86.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. During the same quarter in the previous year, the firm posted $3.13 EPS. The firm’s quarterly revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, research analysts forecast that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s dividend payout ratio is presently 36.48%.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 50,000 shares of the business’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the sale, the director directly owned 2,251,375 shares in the company, valued at approximately $765,692,637.50. The trade was a 2.17% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the sale, the vice president directly owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 355,370 shares of company stock valued at $119,447,201 over the last 90 days. 4.60% of the stock is currently owned by company insiders.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.